Place an order request to the broker. The personal manager will contact you to confirm the order.

Order Summary

Asset: Select instrument
Quantity: -
Price per Unit: ? This price is indicative and shown for informational purposes only. The final execution price may change. -
Total Amount: -

Order Expiration

Order remains active until you cancel it or it gets filled

Order expires at the end of the selected day

Order Placed Successfully

Your order has been submitted! Our team will contact you shortly to confirm.

Order Type: -
Asset: -
Quantity: -
Total Amount: -
Manually record a past trade to keep your portfolio up to date. This helps track your P&L accurately.
Total Amount: $0.00

Trade Added Successfully

Trade recorded! Your portfolio data will be recalculated.

Type: -
Asset: -
Quantity: -
Price: -
Total: -

Chat Options

Web Search
Search the internet for recent information
Portfolio Context
Include your portfolio in the conversation
Market Data
Access real-time market information
Watchlist Context
Include your watchlist companies

Investment Managers Series Trus (IREX)

2026-08-07T05:34:31.908567+00:00

Key Updates

IREX has declined a further 6.70% to $12.96 from $13.89 at the time of the previous report (August 6), extending the post-recovery selloff and approaching the July 31 intraday low of $11.60 — a critical structural support level. The YTD loss now stands at -57.31%, with the 6-month decline at -57.69%, confirming that the brief recovery rally observed in late July/early August has been fully unwound. The investment thesis remains decisively bearish, with no new catalysts to support a reversal.

Current Trend

The dominant trend is unambiguously bearish across all measured timeframes:

  • 1-day: -5.05% — accelerating intraday selling pressure
  • 5-day: -3.28% — sustained short-term weakness
  • 1-month: -23.76% — severe medium-term deterioration
  • 6-month: -57.69% — structural breakdown in progress
  • YTD: -57.31% — IREX has lost more than half its value in 2026

The recovery from the July 31 intraday low of $11.60, which produced a violent +79.30% bounce over five days to approximately $14.90, has been entirely retraced across three consecutive reports. Price is now converging on that prior intraday low, which represents the last identifiable near-term support.

Investment Thesis

IREX operates as a leveraged ETF product within the Investment Managers Series Trust structure. The broader leveraged ETF sector is experiencing simultaneous extremes: record asset inflows and record fund closures. The structural mechanics of leveraged ETFs — daily resets, volatility decay, and compounding losses during volatile or sideways markets — create an inherently hostile environment for long-term holders. IREX's -57.31% YTD performance is consistent with the structural erosion documented across the leveraged ETF category, where even directionally correct bets can result in catastrophic losses due to volatility drag. The sector backdrop, marked by regulatory scrutiny, record closures, and rising retail risk-taking, does not support a recovery thesis at this stage.

Thesis Status

The bearish thesis articulated in prior reports remains fully intact and has strengthened. Each successive report has confirmed the failure of the late-July recovery rally, with IREX now trading within proximity of its cycle low at $11.60. The broader leveraged ETF environment — characterized by 73 fund closures through July 23, 2026 (more than triple all of 2025), and documented instances of single-day losses exceeding 50% — reinforces the structural vulnerability of IREX. No new fundamental catalysts for recovery have emerged. The thesis of continued structural decay driven by volatility compounding and adverse sector dynamics is confirmed.

Key Drivers

The following sector-level and structural factors are driving IREX's continued decline:

  • Record leveraged ETF closures: 73 leveraged/inverse ETFs were shut down through July 23, 2026 — more than triple 2025's full-year total — representing 43% of all U.S.-listed ETF closures this year, signaling acute asset-gathering failure across the category. (Morningstar, July 28)
  • Volatility decay and structural losses: Documented cases show both bullish and bearish leveraged ETFs on the same underlying asset losing ~95% of value while the underlying declined only 38%, illustrating the destructive compounding effect that is directly relevant to IREX's -57% YTD performance. (Business Insider, July 20)
  • Institutional positioning against leveraged ETFs: Research Affiliates founder Rob Arnott is actively positioning against both bullish and bearish leveraged ETF trends, reflecting growing institutional recognition of structural risks — a headwind for retail-driven demand. (Bloomberg, August 4)
  • Regulatory risk escalating globally: South Korea has moved to restrict new leveraged ETF approvals and increase investor requirements following historic market volatility, with leveraged ETFs accounting for up to 35% of daily stock turnover. U.S. regulatory scrutiny is intensifying. (Business Insider, July 20)
  • High fee drag compounding losses: Leveraged ETFs carry 1% management fees plus 5–6% swap costs, creating a structural performance drag that compounds losses during drawdown periods such as IREX's current -57% YTD episode. (Business Insider, July 20)

Technical Analysis

IREX is trading at $12.96, down 6.70% since the last report and down 5.05% on the day. Price action over the past three reporting periods has confirmed a complete failure of the late-July recovery rally, with the fund retracing from approximately $14.90 back toward the July 31 intraday cycle low of $11.60 — now approximately 10.5% below current price. This level represents the only identifiable near-term structural support. A breach of $11.60 on a closing basis would constitute a new cycle low and open downside toward levels not seen in the fund's recent trading history. Resistance is now established at $13.89 (prior report level) and $14.90 (August 5 high). The 1-month decline of -23.76% and 6-month decline of -57.69% confirm that no meaningful technical base has formed. Momentum indicators implied by the consecutive daily declines suggest no capitulation signal has emerged. Volume-driven bounces, as seen in the July 31–August 5 period, have proven unsustainable.

Bull Case

  • 1. Proximity to cycle low support: At $12.96, IREX trades approximately 10.5% above the July 31 intraday low of $11.60 — a level that previously triggered a violent +79.30% short-term bounce, indicating latent technical demand at that price point. (Morningstar, July 28)
  • 2. Sector AUM growth remains robust: Despite closures, the leveraged ETF category has grown to nearly $200 billion in AUM across ~700 products, with the largest fund (ProShares UltraPro QQQ) managing ~$33 billion, indicating that investor demand for the category has not collapsed at the aggregate level. (Morningstar, July 28)
  • 3. Record new product launches signal continued retail appetite: The ETF industry is on pace for a record 1,095 product launches in 2026, with leveraged ETFs representing 31% of all launches in H1 2026 — up from 22% in all of 2025 — suggesting sustained retail interest that could support AUM flows into surviving funds. (Morningstar, July 9)
  • 4. High trading volume concentration: Leveraged ETFs generate 15–20% of daily U.S. ETF trading volume despite representing only 2% of industry assets, indicating disproportionate liquidity and market participation that can support sharp short-term price recoveries. (Morningstar, July 9)
  • 5. Global retail investor base expanding: The Bloomberg report documents a growing cross-border retail investor base — including South Korean retail participants — adopting leveraged ETFs for long-term strategies, broadening the potential demand pool for surviving leveraged products. (Bloomberg, August 4)

Bear Case

  • 1. Structural volatility decay destroying capital systematically: Documented evidence shows leveraged ETFs on the same underlying losing ~95% of value even with only a 38% move in the underlying asset — the same compounding mechanism is the primary driver of IREX's -57.31% YTD loss and will continue to erode value in volatile or range-bound markets. (Business Insider, July 20)
  • 2. Record fund closure rate signals existential AUM risk: 73 leveraged/inverse ETF closures through July 23, 2026 — representing 43% of all U.S. ETF closures and more than triple 2025's full-year total — demonstrate that funds failing to attract assets are being terminated, posing direct closure risk to smaller leveraged products including IREX. (Morningstar, July 28)
  • 3. Escalating regulatory risk domestically and internationally: South Korea has already restricted new leveraged ETF approvals and tightened investor requirements; U.S. regulatory scrutiny is intensifying as leveraged products account for 31% of new ETF launches and generate outsized market volatility — any U.S. regulatory action would be a direct existential threat to IREX. (Business Insider, July 20)
  • 4. Institutional counter-positioning amplifies downside: Rob Arnott of Research Affiliates is actively positioning against both bullish and bearish leveraged ETF trends, and institutional awareness of leveraged ETF structural risks is rising — reducing the probability of institutional support flows that could stabilize IREX. (Bloomberg, August 4)
  • 5. High embedded cost structure compounds losses during drawdowns: The combination of ~1% management fees and 5–6% swap costs creates a structural annual drag of 6–7% that accelerates capital erosion during sustained drawdown periods — directly relevant to IREX's current -57% YTD trajectory and providing a persistent headwind to any recovery. (Business Insider, July 20)

CapPilot is AI-powered and can make mistakes. Please double-check responses.

CapPilot leverages generative AI to distill market insights and analysis, as well as answer your questions in chat. While we work hard to ensure accuracy, AI-generated content may occasionally contain inaccuracies or outdated information.

We value your feedback — reporting errors helps us continuously improve.